Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 4 Interventional

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

ClinicalTrials.gov ID: NCT06572228

Public ClinicalTrials.gov record NCT06572228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AIM4: Next Step - Asthma Uncontrolled With ICS in Medium Dose (GINA 4): Next Step; Efficacy of Dupilumab Added to Medium Dose ICS/LABA in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Patients With Uncontrolled Asthma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab

Study identification

NCT ID
NCT06572228
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 4
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
120 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 26, 2024 (Actual)
Primary completion
Apr 24, 2027 (Estimated)
Completion
Apr 24, 2027 (Estimated)
Last update posted
May 22, 2026

2024 – 2027

United States locations

U.S. sites
51
U.S. states
22
U.S. cities
50
Facility City State ZIP Site status
Kern Research, Inc Bakersfield California 93301 —
Modena Allergy & Asthma, Inc. La Jolla California 92037 —
Antelope Valley Clinical Trials Lancaster California 93534 —
Ark Clinical Research, LLC Long Beach California 90815 —
Newport Native Md, Inc. Newport Beach California 92663 —
Childrens Hospital of Orange County Main Campus Orange California 92868 —
Raffi Tachdjian MD, Inc. Santa Monica California 90404 —
Bensch Clinical Research Stockton California 95207 —
Integrated Research of Inland, Inc. Upland California 91786 —
Allianz Research Institute Westminster California 92683 —
National Jewish Health Denver Colorado 80206 —
St Francis Medical Institute Clearwater Florida 33765 —
Florida Lung, Asthma and Sleep Specialists (FLASS) - Celebration Kissimmee Florida 34746 —
Clinical Site Partners, LLC DBA Flourish Research Winter Park Florida 32789 —
Treasure Valley Medical Research Boise Idaho 83706 —
Sneeze Wheeze and Itch Associates Normal Illinois 61761 —
Asthma and Allergy Center of Chicago River Forest Illinois 60305 —
Endeavor Health, Skokie Campus Skokie Illinois 60077 —
University of Kansas Medical Center Kansas City Kansas 66160 —
Bluegrass Allergy Research Lexington Kentucky 40509 —
Family Allergy and Asthma Research Institute Louisville Kentucky 40217 —
Allergy & Asthma Specialists, P.S.C. Owensboro Kentucky 42301 —
Paul A. Shapero, M.D. Bangor Maine 04401 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Michigan Medicine Ann Arbor Michigan 48109 —
Henry Ford Hospital Detroit Michigan 48202 —
Clinical Research Institute, Inc. Minneapolis Minnesota 55402 —
Washington University School of Medicine St Louis Missouri 63119 —
Montana Medical Research Missoula Montana 59808 —
The Asthma and Allergy Center Bellevue Nebraska 68123 —
Henderson Clinical Trials Henderson Nevada 89052 —
Certified Research Associates Cortland New York 13045 —
New York Medical College Hawthorne New York 10532 —
Northwell Health at ENT & Allergy Associates New York New York 10016 —
Rochester Regional Health - Alexander Park - Allergy, Immunology & Rheumatology Rochester New York 14607 —
Cincinnati Childrens Hospital and Medical Center Cincinnati Ohio 45229 —
Allergy Asthma and Clinical Research Center Oklahoma City Oklahoma 73120 —
Clinical Research Associates of Central PA DuBois Pennsylvania 15801 —
University of Pittsburgh Asthma and Environmental Health Lung Institute Pittsburgh Pennsylvania 15213 —
Pulmonology Associates Inc. Wynnewood Pennsylvania 19096 —
Dharma MD PA d/b/a Southwest Family Medicine Associates Dallas Texas 75235 —
Premier Pulmonary Critical Care and Sleep Medicine Denison Texas 75020 —
Western Sky Medical Research El Paso Texas 79912 —
Baylor College of Medicine - Section of Pulmonary and Critical Care Houston Texas 77030 —
Texas Children's Hospital Houston Texas 77030 —
Metroplex Pulmonary and Sleep Center, PA McKinney Texas 75069 —
Lung Sleep Research Institute North Richland Hills Texas 76180 —
South Texas Allergy & Asthma Medical Professionals (STAAMP) Research San Antonio Texas 78229 —
Allergy & Asthma Care of Waco Waco Texas 76712 —
Intermountain Medical Center - Murray (Pulmonary Medicine) Murray Utah 84107 —
Inova Fairfax Hospital Falls Church Virginia 22042 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06572228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 22, 2026 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06572228 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →